Vanguard U.S. Momentum Factor ETF (NY:VFMO)

245.16 -4.34 (-1.74%)

Streaming Delayed Price Updated: 12:41 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 3 Next >

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗

August 13, 2025

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Via Stocktwits

Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming ↗

August 05, 2025

Via Stocktwits

Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity ↗

August 05, 2025

Via Stocktwits

Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price ↗

July 22, 2025

Via Stocktwits

Hims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent Expires ↗

July 09, 2025

The telehealth company stated that its entry to Canada will come as generic semaglutide hits the market for the first time.

Via Stocktwits

Topics Intellectual Property

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity ↗

July 09, 2025

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Via Stocktwits

Topics Government

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated ↗

July 07, 2025

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous...

Via Stocktwits

AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report ↗

July 03, 2025

While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that...

Via Stocktwits

5 Surprising Vanguard ETFs That Could Beat the Market ↗

February 20, 2025

Not all Vanguard ETFs are the index funds you're probably familiar with.

Via The Motley Fool

Topics ETFs

After Beating the S&P 500 in 2024, This Vanguard Growth ETF Is Already Up Over 6% in 2025 ↗

January 28, 2025

Via The Motley Fool

Topics ETFs Stocks

Don't Miss This Actively Managed Vanguard ETF That Could Supercharge Your Returns ↗

October 26, 2024

This Vanguard fund could help diversify your ETF portfolio.

Via The Motley Fool

Topics ETFs

Vanguard ETFs: An Overview ↗

April 27, 2024

This ETF family is renowned for high capital returns, low expenses, and upholding management practices that prioritize shareholder interests.

Via The Motley Fool

Topics ETFs

This Is the Perfect Vanguard ETF for Investors With a Fear of Missing Out on the Market's Biggest Winners ↗

April 06, 2024

Don't fear: There's an ETF that will ensure you don't miss out on any high-flying stocks.

Via The Motley Fool

Topics ETFs

Like the "Magnificent Seven" Stocks? You'll Love This Vanguard ETF. ↗

March 25, 2024

This Vanguard ETF is a great way to invest in momentum stocks.

Via The Motley Fool

Topics ETFs

ETF Battles: Looking For The Best Momentum Stock ETF? It's MTUM vs. MTMM vs. JMOM vs. VFMO! ↗

January 23, 2022

In this episode of ETF Battles, Ron DeLegge @ETFguide referees an audience requested quadruple-header duel between 4 momentum focused stock ETFs.

Via Talk Markets

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.